

# MEDIA RELEASE

---

## RESMED COMMENTS ON EARNINGS FORECAST

---

SYDNEY, Australia, April 29, 2004... ResMed Inc. (ASX: RMD) announced today that at a meeting of business executives on April 29th in Sydney, Peter C. Farrell, Ph.D., ResMed Inc.'s Chairman of the Board and Chief Executive Officer, stated that, in his view, analyst estimates of ResMed's net profit for the fiscal year ending June 30, 2004, of approximately \$56 million "are not silly." Dr. Farrell also announced that ResMed is considering de-listing from the Australian Stock Exchange due to the expenses associated with complying with two sets of listing requirements, particularly given differences in the regulatory requirements, and the potential impact ResMed's policy of not paying dividends may have on its trading price in Australia.

ResMed is a leading developer, manufacturer, and marketer of medical equipment for the diagnosis, treatment, and management of sleep-disordered breathing, selling a comprehensive range of products in over 60 countries.

Further information can be obtained by contacting Adrian Smith at ResMed Inc. Sydney on (02) 9886-5407; or by visiting the Company's multilingual Web site at [www.resmed.com](http://www.resmed.com).

Statements contained in this report, which are not historical facts, are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including statements regarding the company's future net profit projections and possible changes in the company's listing status in Australia, are subject to risks and uncertainties which could cause actual results to differ materially from those projected or implied in the forward-looking statements, and consequently there can be no assurance that the net profit estimate will be met. Among the factors that could affect actual performance are the rate of growth of the sleep disordered breathing market, the company's ability to penetrate this market, fluctuations in foreign currency exchange rates and developments by the company's competitors. Such risks and uncertainties are discussed in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2003, and Quarterly Reports on Form 10-Q for the fiscal quarters ended September 30, 2003 and December 31, 2003.

###